N/A
Completed N=506
Improving Medication Adherence Among Underserved Patients With Type 2 Diabetes
Source: ClinicalTrials.gov NCT02409329 ↗Enrolled (actual)
506
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcomePrimary: Change in Glycemic Control as Indicated by Hemoglobin A1c (HbA1c) — 8.29; 8.59; 8.32; 8.57 percent — p=.0493
Summary
This study evaluates a mobile phone-delivered intervention, called REACH (Rapid Education/Encouragement And Communications for Health), in supporting adults with type 2 diabetes in their self-management relative to a control group. The goal of this study is to determine if individually tailored content (based on the Information-Motivation-Behavioral Skills Model) delivered to the participant via text messages can improve the participant's glycemic control and adherence to diabetes medications. We will test whether our intervention improves adherence-related information, motivation, and behavioral skills and whether improving these mechanisms drives improvements in adherence and, in turn, glycemic control.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Glycemic Control as Indicated by Hemoglobin A1c (HbA1c) |
8.29; 8.59; 8.32; 8.57; 8.66; 8.70 | .0493 sig |
| SECONDARY Change in Self-reported Medication Adherence |
40.4; 40.4; 40.6; 40.2; 40.3; 40.2 | 0.376 |
Eligibility Criteria
Inclusion Criteria
- Adults aged 18 years and older
- Individuals who have received a diagnosis for type 2 diabetes mellitus
- Enrolled as a patient at a participating community health center
- Individuals currently being treated with oral and/or injectable diabetes medications
Exclusion Criteria
- Non-English speakers
- Individuals who report they do not have a cell phone
- Individuals unwilling and/or not able to provide written informed consent
- Individuals with unintelligible speech (e.g., dysarthria)
- Individuals with a severe hearing or visual impairment
- Individuals who report a caregiver administers their diabetes medications Individuals who fail the cognitive screener administered during the baseline survey
- Individuals who cannot receive, read, and respond to a text after instruction from a trained research assistant
- Individuals whose most recent (within 12 months) HbA1c value was 6.8% or greater
Data sourced from ClinicalTrials.gov (NCT02409329). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.